PARP inhibitor with or without an angiogenesis inhibitor for HRD advanced ovarian, fallopian-tube, or primary peritoneal cancer
To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.
This trial will test whether adding the angiogenesis drug bevacizumab to a PARP inhibitor helps people with homologous recombination deficient (HRD) stage III–IV ovarian, fallopian-tube, or primary peritoneal cancer.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | N.N. Alexandrov National Cancer Centre Government |
| Drugs / interventions | bevacizumab, chemotherapy |
| Locations | 1 site (Minsk, Lesnoy) |
| Trial ID | NCT07472140 on ClinicalTrials.gov |
What this trial studies
This is a randomized Phase 2/3 trial comparing a PARP inhibitor alone versus a PARP inhibitor combined with the angiogenesis inhibitor bevacizumab in people with HRD high-grade serous or endometrioid ovarian, fallopian-tube, or primary peritoneal cancer. Eligible participants are adults with stage III–IV disease, ECOG 0–1, and no contraindications to chemotherapy or bevacizumab. The study includes surgical assessment (diagnostic laparoscopy or cytoreductive surgery) and regular follow-up to monitor tumor response, progression-free survival, and safety. Treatment tolerability and rates of disease control will be compared between the two groups.
Who should consider this trial
Good fit: Adults age 18–75 with histologically confirmed high-grade serous or endometrioid ovarian, fallopian-tube, or primary peritoneal cancer, stage III–IV, proven HRD, ECOG 0–1, eligible for diagnostic laparoscopy or cytoreductive surgery, and with no contraindication to chemotherapy or bevacizumab.
Not a fit: People without homologous recombination deficiency, those with another active invasive cancer, pregnant or breastfeeding individuals, or those whose disease progressed during prior treatment are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, the combination could extend the time without cancer growth and reduce recurrence risk for people with HRD advanced ovarian-type cancers.
How similar studies have performed: Similar combinations have shown benefit in HRD ovarian cancer—for example, the PAOLA-1 Phase 3 trial reported improved progression-free survival with olaparib plus bevacizumab in HRD patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18-≤75 years. * Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Possibility of performing diagnostic laparoscopy or cytoreductive surgery. * Presence of homologous recombination deficiency (HRD). * No contraindications to chemotherapy, or bevacizumab. * Signed informed consent to participate in the study. Exclusion Criteria: * Presence of another active malignant invasive neoplasm. * Pregnancy or lactation period. * Disease progression during treatment.
Where this trial is running
Minsk, Lesnoy
- N.N. Alexandrov National Caner Centre — Minsk, Lesnoy, Belarus (Recruiting)
Study contacts
- Study coordinator: Hanna Trukhan
- Email: annavladimir@rambler.ru
- Phone: 80291985715
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.